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International clinical guidelines reinforce the overwhelming opinion that chronic obstructive pulmonary disease (COPD) is a manageable and treatable disease for patients with all grades of disease severity. ADDIN EN.CITE 1  This is a very hopeful and optimistic notion given that smoking cessation is the most effective intervention for managing COPD to-date, and the only intervention yet shown to slow the rate of lung function decline. ADDIN EN.CITE ,  While it has been reported that pharmacological therapy can improve lung function and reduce COPD symptoms, ADDIN EN.CITE 4 COPD exacerbations and hospitalizations, ADDIN EN.CITE , the effects are not strong and therapeutic developments still lag behind other major chronic illnesses. Palliative treatments such as oxygen therapy7 and lung volume reduction either surgically8 or using interventional bronchoscopic valve placement ADDIN EN.CITE 9 also independently offer a survival advantage for some patients with very severe disease.  Despite the modest efficacy reported using existing management strategies, COPD hospitalization and mortality rates continue to rise, most strikingly in women,10 and health economists warn that this upward trend will continue and very soon overwhelm our healthcare systems.11  In light of this dire situation, new COPD management strategies are being actively pursued and investigated to combat this growing public health emergency.
With precision medicine methods on the horizon for all patients with chronic disease, there is a renewed optimism for the possibility of finding new ways to reduce the burden of COPD.  Precision medicine depends on a deeper understanding of the individual patient’s genetic background and the gene-environment interactions that lead to specific underlying biological processes – the disease “endotype” (ie. inflammation).  By understanding how these distinct underlying biological processes manifest in the individual patient – the disease “phenotype” (ie. emphysema) – it is thought that precision medicine will enable the “right” treatment to be provided to the right patient at the right time.  A better understanding of underlying disease endotypes will not only allow for better patient management, but will also open doors for the discovery of new drugs/interventions and clinical trials that target the underlying pathologies embodied by chronic lung disease.  Furthermore, linking the endotype to the phenotype will enable the identification and stratification of patients with certain disease features for clinical trials of targeted treatments, as well as evaluation of treatment efficacy.  In light of this, there is renewed interest in the development and evaluation of the COPD phenotype measurements.  In patients with COPD, such phenotype measurements currently include clinical and functional biomarkers as well as recently discovered pulmonary imaging biomarkers.  
The technical development, clinical and commercial translation of medical imaging technologies and the more recent development of quantitative imaging methods, have led to their increased use in the diagnosis and management of many chronic diseases.  Until very recently however, for patients with COPD, medical imaging has not played a major role outside the setting of acute complications or lung cancer diagnosis.  Therefore, in this review we highlight three pulmonary imaging modalities: computed tomography (CT), magnetic resonance imaging (MRI) and optical coherence tomography (OCT) imaging and the COPD biomarkers that may be helpful for managing COPD patients.  By summarizing how imaging is currently used in COPD patient management and its potential to play a larger role in COPD phenotyping and treatment decisions, we endeavour to answer the question: Is there a role for quantitative imaging in patients with COPD? 

X-ray Computed Tomography Measurements and Biomarkers of COPD
For over a decade, the clinical standard for COPD patient imaging has been high resolution x-ray computed tomography (CT).  Pulmonary CT enables the direct and regional quantification of a number of COPD pathologic features and biomarkers that are relevant to the evaluation and management of COPD patients.
Parenchyma Microstructure: Emphysema
Regional tissue destruction or emphysema is very common in COPD patients and appear as regions of low attenuation on CT images acquired at suspended full-inspiration.  To quantify low attenuating regions, the most commonly used approaches make use of the histogram of all CT densitometry values in the lung and a CT density threshold cut-off or a percentile of the CT density histogram to generate “CT density masks.”  Although various threshold values and percentile points have been investigated, the -950HU threshold ADDIN EN.CITE 12-14 and the 15th percentile on the frequency distribution curve ADDIN EN.CITE 15  are the most widely accepted. ADDIN REFMGR.CITE    
A limitation of CT histogram measurement approaches for quantifying the extent of emphysema is that these do not take into account the size of the low attenuation areas in the lung or how they cluster together, which may be an important consideration in COPD patient management.  One approach that does account for clusters of values is the analysis of low attenuation clusters (LAC) ADDIN EN.CITE 16, ADDIN EN.CITE 17 which quantifies low attenuation regions as “emphysematous holes.” Studies show that the LAC measurement is correlated with mathematical models of emphysematous cluster formation and agrees with radiologist emphysema scores. ADDIN EN.CITE 18-20  
Figure 1A shows a centre slice, coronal CT image with all lung voxels less than the -950HU threshold highlighted in red.  The three-dimensional reconstruction of the CT airway tree and the low attenuation clusters (colour-coded for the different lung lobes) are shown below in Figure 1B.  Although it is clear in the CT density mask for the subject with moderate and severe COPD that emphysema is located predominantly in the upper and middle lobes, the LAC analysis provides both a visual representation of the localized disease, depicted as large spheres in regions corresponding to greater spatial clustering of the emphysematous lesions, as well as a quantitative measurement.
Large Airways
Airways disease is another important pathological feature in patients with COPD, and the proximal airways can be directly visualized and quantified using low dose thoracic CT methods.  Several approaches have been used to segment the airway tree and then quantify the airway wall dimensions, such as threshold-based analysis21 and full-width at half maximum algorithm,22 subsequent to three-dimension reconstruction of the airway tree. ADDIN EN.CITE 23-25  While many of these algorithms are still experimental, several have been incorporated into commercially-available software including VIDA Diagnostics, Inc. (Coralville, IA, USA), FLUIDDA (North Brunswick, NU, USA), Pulmo3D Software (Fraunhofer MEVIS, Bremen, Germany), and Airway Inspector (Harvard Medical School, Boston, MA).
There is a wealth of quantitative airway dimension measurements that can be obtained from CT images.  One of the measurements used in clinical research is the mean airway wall area (WA), or airway wall area expressed as a percentage (WA%), which was shown to be significantly correlated with histological measures of the small airways. ADDIN EN.CITE 26  However, the anatomical locations within the airway tree where WA measurements are obtained vary across studies, from a single airway location (eg. RB1 ADDIN EN.CITE 27) to an average of all airways of a particular generation (eg. 5th generation airways ADDIN EN.CITE 28), and therefore it is difficult to compare measurements between studies.  Furthermore, it is difficult to compare this measurement between patients because there are different distributions of airway sizes in different patients.  Another common CT airway measurement was introduced to avoid the potential bias that occurs due to the different distribution of airway sizes is a standardized measure for airway wall thickness.29  This measure, called the Pi10, is derived by plotting the square root of the airway wall area versus the internal perimeter of each measured airway and using the regression line to calculate the square root of the airway wall area for a representative airway with an internal perimeter of 10mm.  More recently, Smith and colleagues ADDIN EN.CITE 30 proposed another way to overcome this potential measurement bias by only including measurements from airway segments that were anatomically matched for all subjects.  
Most commercially available lung analysis software, such as is shown in Figure 1C (Apollo, VIDA Diagnostics Inc. Coralville, IA, USA), allows the three-dimensional reconstruction and labeling of the airway branching structure.  This approach allows investigators to select an individual airway (e.g. RB1) and obtain specific regional airway measurements.
Functional Small Airways Disease
It has long been known that small airway obstruction may be identified using evidence of CT lucency, or gas trapping, on CT expiratory images in the absence of emphysema. ADDIN EN.CITE 31  Although numerous approaches have been evaluated, including the inspiratory-to-expiratory volume change of voxels with attenuation values from -860 to -950 HU (RVC-860 to -950) ADDIN EN.CITE 32 and the expiratory-to-inspiratory ratio of mean lung density in HU (E/I ratio), ADDIN EN.CITE , a more regionally quantitative approach was recently introduced.  This approach provides a way to quantify regional gas trapping, or “functional small airways disease,” on a voxel-by-voxel basis by registration of the full-inspiration and full-expiration thoracic CT images. ADDIN EN.CITE ,  While measurements generated using this approach have not yet been histologically validated, such measurements were shown to be reproducible over short periods of time, ADDIN EN.CITE 37 they correlated with pulmonary function,,  showed spatial agreement with functional abnormalities identified with other imaging modalities,38 and were associated with longitudinal changes in FEV1. ADDIN EN.CITE 39  
Functional Information:  Dual-Energy CT
Conventional anatomical CT cannot provide direct information regarding which parts of the lung receive ventilation or perfusion – functional information.  Therefore, other approaches such as dual-energy CT (DECT) ADDIN EN.CITE 40-42 are being developed and evaluated.  A recent study investigating DECT with combined xenon-enhanced ventilation and iodine contrast enhanced perfusion imaging demonstrated the feasibility of obtaining regional and quantitative ventilation and perfusion measurements and, importantly, the measurements of the ventilation-perfusion relationship on a voxel-by-voxel basis.43  In patients with COPD, these DECT ventilation-perfusion measurements were shown to be significantly associated with measures of pulmonary function.43

Magnetic resonance Imaging Measurements of COPD
There is growing interest in the use of pulmonary MRI for research, not only because of the relative speed in which images can be generated, and excellent safety and tolerability profile, ADDIN EN.CITE ,HYPERLINK \l "_ENREF_33" \o "Shukla, 2012 #1173" but also because of the unique combination of morphological and functional information MRI provides.  Morpho-functional pulmonary measurements can be achieved using conventional 1H MRI using the inherent signal of the parenchyma.  In addition, functional information may also be derived using physiologic signal alterations such as pulsatile blood flow or ventilation stemming from the 1H MRI signal itself or using intravenous or inhaled contrast agents.
Non-contrast Enhanced 1H MRI
Clinical non-contrast enhanced 1H MRI is used to visualize and detect tissue abnormalities in the body.  However, direct visualization of lung tissue is difficult due to the low proton density and rapid signal decay due to the very short transverse magnetization relaxation time (T2*) of aerated lung tissue. HYPERLINK \l "_ENREF_46" \o "Wild, 2012 #2108"  ADDIN EN.CITE <EndNote><Cite><Author>Wild</Author><Year>2012</Year><RecNum>2108</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>2108</rec-number><foreign-keys><key app="EN" db-id="zvx0p0vtmtxre0esfsrxfevg0rafdvdtz90s">2108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wild, J. M.</author><author>Marshall, H.</author><author>Bock, M.</author><author>Schad, L. R.</author><author>Jakob, P. M.</author><author>Puderbach, M.</author><author>Molinari, F.</author><author>Van Beek, E. J.</author><author>Biederer, J.</author></authors></contributors><auth-address>Academic Radiology, Royal Hallamshire Hospital Sheffield, University of Sheffield, Sheffield, S10 2JF, UK, j.m.wild@sheffield.ac.uk.</auth-address><titles><title>MRI of the lung (1/3): methods</title><secondary-title>Insights Imaging</secondary-title><alt-title>Insights into imaging</alt-title></titles><periodical><full-title>Insights Imaging</full-title><abbr-1>Insights into imaging</abbr-1></periodical><alt-periodical><full-title>Insights Imaging</full-title><abbr-1>Insights into imaging</abbr-1></alt-periodical><pages>345-53</pages><volume>3</volume><number>4</number><edition>2012/06/15</edition><dates><year>2012</year><pub-dates><date>Aug</date></pub-dates></dates><isbn>1869-4101 (Electronic)&#xD;1869-4101 (Linking)</isbn><accession-num>22695952</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22695952</url></related-urls></urls><custom2>3481083</custom2><electronic-resource-num>10.1007/s13244-012-0176-x</electronic-resource-num><language>eng</language></record></Cite></EndNote>46 This results in multiple susceptibility artifacts at air-tissue interfaces of the alveoli.  Therefore, clinical MRI for pulmonary applications necessarily focuses on abnormalities with high signal intensity against the dark background of the lung tissue. HYPERLINK \l "_ENREF_47" \o "Biederer, 2012 #4547"  ADDIN EN.CITE <EndNote><Cite><Author>Biederer</Author><Year>2012</Year><RecNum>4547</RecNum><DisplayText><style face="superscript">47</style></DisplayText><record><rec-number>4547</rec-number><foreign-keys><key app="EN" db-id="zvx0p0vtmtxre0esfsrxfevg0rafdvdtz90s">4547</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Biederer, J.</author><author>Beer, M.</author><author>Hirsch, W.</author><author>Wild, J.</author><author>Fabel, M.</author><author>Puderbach, M.</author><author>Van Beek, E. J.</author></authors></contributors><auth-address>University Hospital Schleswig-Holstein, Campus Kiel, Department of Diagnostic Radiology, Arnold-Heller-Strasse 3, Haus 23, 24105, Kiel, Germany, juergen.biederer@rad.uni-kiel.de.</auth-address><titles><title>MRI of the lung (2/3). Why ... when ... how?</title><secondary-title>Insights Imaging</secondary-title></titles><periodical><full-title>Insights Imaging</full-title><abbr-1>Insights into imaging</abbr-1></periodical><pages>355-71</pages><volume>3</volume><number>4</number><dates><year>2012</year><pub-dates><date>Aug</date></pub-dates></dates><isbn>1869-4101 (Electronic)&#xD;1869-4101 (Linking)</isbn><accession-num>22695944</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22695944</url></related-urls></urls><custom2>3481084</custom2><electronic-resource-num>10.1007/s13244-011-0146-8</electronic-resource-num></record></Cite></EndNote>47  For example, fluid accumulation or solid pathology and atelectasis are visualized with excellent signal-to-background ratio.  Lung tissue abnormalities in COPD patients such as focal emphysema, bronchiectasis and consolidation may be detected and quantified/scored using MRI despite a slightly lower spatial resolution compared to CT. HYPERLINK \l "_ENREF_48" \o "Barreto, 2013 #4549"  ADDIN EN.CITE <EndNote><Cite><Author>Barreto</Author><Year>2013</Year><RecNum>4549</RecNum><DisplayText><style face="superscript">48</style></DisplayText><record><rec-number>4549</rec-number><foreign-keys><key app="EN" db-id="zvx0p0vtmtxre0esfsrxfevg0rafdvdtz90s">4549</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Barreto, M. M.</author><author>Rafful, P. P.</author><author>Rodrigues, R. S.</author><author>Zanetti, G.</author><author>Hochhegger, B.</author><author>Souza, A. S., Jr.</author><author>Guimaraes, M. D.</author><author>Marchiori, E.</author></authors></contributors><auth-address>Department of Radiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</auth-address><titles><title>Correlation between computed tomographic and magnetic resonance imaging findings of parenchymal lung diseases</title><secondary-title>Eur J Radiol</secondary-title></titles><periodical><full-title>Eur J Radiol</full-title><abbr-1>European journal of radiology</abbr-1></periodical><pages>e492-501</pages><volume>82</volume><number>9</number><keywords><keyword>Diagnosis, Differential</keyword><keyword>Humans</keyword><keyword>Image Enhancement/*methods</keyword><keyword>Lung/*pathology/*radiography</keyword><keyword>Lung Diseases, Interstitial/*diagnosis</keyword><keyword>Magnetic Resonance Imaging/*methods</keyword><keyword>Statistics as Topic</keyword><keyword>Tomography, X-Ray Computed/*methods</keyword><keyword>Computed tomography</keyword><keyword>Imaging</keyword><keyword>Lung diseases</keyword><keyword>Magnetic resonance</keyword></keywords><dates><year>2013</year><pub-dates><date>Sep</date></pub-dates></dates><isbn>1872-7727 (Electronic)&#xD;0720-048X (Linking)</isbn><accession-num>23763860</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/23763860</url></related-urls></urls><electronic-resource-num>10.1016/j.ejrad.2013.04.037</electronic-resource-num></record></Cite></EndNote>48  Already in clinical use, steady state gradient echo and T2-weighted fast spin echo techniques help to differentiate healthy lung tissue from focal emphysema, bullae and pneumothorax. ADDIN EN.CITE ,  Beyond such “clinical” scans, experimental pulmonary MRI offers tremendous flexibility in the type of images and information that can be obtained.  
One approach used to generate images with greater signal from the lung parenchyma involves pulse sequences that incorporate ultra-short echo times or UTE MRI.49  Short echo times (TE) or zero-echo times (where echo time is typically defined as the time between the end of radiofrequency excitation and the beginning of data acquisition), effectively reduce 1H signal loss from the lung parenchyma.  As a result, UTE MR images may be used to identify many of the same pulmonary pathological features as CT. ADDIN EN.CITE ,  Measurements generated using this approach often quantify the 1H signal intensity directly52 or T2*. ADDIN EN.CITE 53  Longitudinal relaxation times (T1) themselves may be used for direct quantitative imaging of lung parenchyma alterations in COPD. ADDIN EN.CITE 54  Studies have determined that in COPD patients there are significantly shorter T1-relaxation times and intra-individual regional differences of T1 correspond to lung parenchyma differences on CT at the lobar or segmental level. ADDIN EN.CITE ,
Regarding functional information, fast-time-resolved imaging (obtained with gradient echo or steady state gradient echo based sequences) can be used to detect impaired respiratory mechanics. ADDIN EN.CITE ,  Regional ventilation maps can also be generated using volumetric analysis of inspiratory and expiratory 4D data sets. ADDIN EN.CITE 57  Moreover, the inherent signal alterations from blood flow may be used to generate lung perfusion maps.  Arterial spin labeling (ASL) uses the intrinsic contrast of magnetized, inflowing blood into the imaging plane or volume. Since ASL does not rely on exogenous contrast, it may be used for serial or longitudinal studies with virtually unlimited repetition of measurements. HYPERLINK \l "_ENREF_58" \o "Mai, 1999 #4561"  ADDIN EN.CITE <EndNote><Cite><Author>Mai</Author><Year>1999</Year><RecNum>4561</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>4561</rec-number><foreign-keys><key app="EN" db-id="zvx0p0vtmtxre0esfsrxfevg0rafdvdtz90s">4561</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mai, V. M.</author><author>Hagspiel, K. D.</author><author>Christopher, J. M.</author><author>Do, H. M.</author><author>Altes, T.</author><author>Knight-Scott, J.</author><author>Stith, A. L.</author><author>Maier, T.</author><author>Berr, S. S.</author></authors></contributors><auth-address>Department of Radiology, University of Virginia Health Sciences Center, Charlottesville 22908, USA.</auth-address><titles><title>Perfusion imaging of the human lung using flow-sensitive alternating inversion recovery with an extra radiofrequency pulse (FAIRER)</title><secondary-title>Magn Reson Imaging</secondary-title></titles><periodical><full-title>Magn Reson Imaging</full-title><abbr-1>Magnetic resonance imaging</abbr-1></periodical><pages>355-61</pages><volume>17</volume><number>3</number><keywords><keyword>Adult</keyword><keyword>Blood Flow Velocity/physiology</keyword><keyword>*Contrast Media</keyword><keyword>Diffusion</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>*Image Enhancement</keyword><keyword>Lung/*blood supply</keyword><keyword>*Magnetic Resonance Imaging</keyword><keyword>Male</keyword><keyword>Reference Values</keyword><keyword>Regional Blood Flow/physiology</keyword><keyword>*Spin Labels</keyword></keywords><dates><year>1999</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>0730-725X (Print)&#xD;0730-725X (Linking)</isbn><accession-num>10195578</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/10195578</url></related-urls></urls></record></Cite></EndNote>58  However, pulmonary ASL imaging has not yet made its way into clinical applications, and successful implementation in COPD patients has not been reported. HYPERLINK \l "_ENREF_59" \o "Molinari, 2008 #4566"  ADDIN EN.CITE <EndNote><Cite><Author>Molinari</Author><Year>2008</Year><RecNum>4566</RecNum><DisplayText><style face="superscript">59</style></DisplayText><record><rec-number>4566</rec-number><foreign-keys><key app="EN" db-id="zvx0p0vtmtxre0esfsrxfevg0rafdvdtz90s">4566</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Molinari, F.</author><author>Puderbach, M.</author><author>Eichinger, M.</author><author>Ley, S.</author><author>Fink, C.</author><author>Bonomo, L.</author><author>Kauczor, H. U.</author><author>Bock, M.</author></authors></contributors><auth-address>Department of Bioimaging and Radiological Sciences, Catholic University of Rome, Rome, Italy. fmolinari@rm.unicatt.it</auth-address><titles><title>Oxygen-enhanced magnetic resonance imaging: influence of different gas delivery methods on the T1-changes of the lungs</title><secondary-title>Invest Radiol</secondary-title></titles><periodical><full-title>Invest Radiol</full-title><abbr-1>Investigative radiology</abbr-1></periodical><pages>427-32</pages><volume>43</volume><number>6</number><keywords><keyword>Administration, Inhalation</keyword><keyword>Adult</keyword><keyword>Feasibility Studies</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Magnetic Resonance Imaging/*methods</keyword><keyword>Male</keyword><keyword>*Masks</keyword><keyword>Oxygen/*administration &amp; dosage</keyword><keyword>Pulmonary Gas Exchange/physiology</keyword><keyword>Pulmonary Ventilation/physiology</keyword><keyword>Respiratory Function Tests</keyword><keyword>Statistics, Nonparametric</keyword></keywords><dates><year>2008</year><pub-dates><date>Jun</date></pub-dates></dates><isbn>0020-9996 (Print)&#xD;0020-9996 (Linking)</isbn><accession-num>18496048</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/18496048</url></related-urls></urls><electronic-resource-num>10.1097/RLI.0b013e318169012d</electronic-resource-num></record></Cite></EndNote>59
Fourier Decomposition MRI ADDIN EN.CITE , is another recently introduced 1H-based MRI approach. This technique acquires images during free breathing and then co-registers the images such that the changes in MR signal intensity over time in each voxel due to the breathing and cardiac cycle can be decomposed to yield ventilation-weighted and perfusion-weighted MR images. In ventilation-weighted images, measurements of the “ventilation defects” have been shown to agree well with dynamic contrast enhanced MRI in patients with cystic fibrosis62 and with hyperpolarized 3He MRI and CT emphysema measurements in patients with COPD. ADDIN EN.CITE 63
Oxygen-enhanced 1H MRI
Oxygen-enhanced MRI exploits the signal inherent to T1 signal alterations stemming from the presence of O2 in tissue and air. Pulmonary 1H images obtained during inhalation of different concentrations of O2 (i.e., room air and 100% of O2) can be subtracted to depict signal changes in the ventilated lung related to a combination of ventilation, membrane function, and perfusion effects. ADDIN EN.CITE , HYPERLINK \l "_ENREF_64" \o "Edelman, 1996 #193"   In COPD patients, Ohno and colleagues65 demonstrated that measurements of the mean relative enhancement ratio (the difference in signal intensity between images acquired during 100% oxygen and room-air breathing, normalized to the signal intensity of room air breathing) showed greater heterogeneity in subjects with emphysema compared to healthy volunteers.   
1H MRI with Application of Intravenous Contrast Material
First pass perfusion contrast-enhanced imaging uses an intravenous bolus injection of a clinically approved contrast medium based on gadolinium chelates. The bolus is injected during continuous acquisition of time-resolved T1-weighted ultrashort TR and TE gradient-echo (GRE) imaging. When incorporated with parallel imaging and view-sharing technology, dynamic volume studies (one full lung volume/second) can be employed. The visual evaluation of the image sets is facilitated by subtraction of the non-enhanced from the contrast-enhanced image signal, which results in a bright display of the contrast-enhanced lung vessels and parenchyma. ADDIN EN.CITE 66 Lung perfusion deficits due to hypoxic vasoconstriction are used for the indirect visualization of ventilation defects in obstructive lung disease. Furthermore, visualizing perfusion dynamically during image acquisition not only allows for perfusion abnormalities to be detected at peak enhancement, but also for other conditions such as delayed perfusion to be detected. HYPERLINK \l "_ENREF_67" \o "Risse, 2011 #4576"  ADDIN EN.CITE <EndNote><Cite><Author>Risse</Author><Year>2011</Year><RecNum>4576</RecNum><DisplayText><style face="superscript">67</style></DisplayText><record><rec-number>4576</rec-number><foreign-keys><key app="EN" db-id="zvx0p0vtmtxre0esfsrxfevg0rafdvdtz90s">4576</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Risse, F.</author><author>Eichinger, M.</author><author>Kauczor, H. U.</author><author>Semmler, W.</author><author>Puderbach, M.</author></authors></contributors><auth-address>Department of Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany.</auth-address><titles><title>Improved visualization of delayed perfusion in lung MRI</title><secondary-title>Eur J Radiol</secondary-title></titles><periodical><full-title>Eur J Radiol</full-title><abbr-1>European journal of radiology</abbr-1></periodical><pages>105-10</pages><volume>77</volume><number>1</number><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Child</keyword><keyword>Contrast Media</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Image Enhancement/*methods</keyword><keyword>Imaging, Three-Dimensional/*methods</keyword><keyword>Lung/blood supply/*pathology</keyword><keyword>Lung Diseases/*diagnosis</keyword><keyword>Magnetic Resonance Angiography/*methods</keyword><keyword>Male</keyword><keyword>Pulmonary Artery/*pathology</keyword><keyword>Reproducibility of Results</keyword><keyword>Sensitivity and Specificity</keyword><keyword>Young Adult</keyword></keywords><dates><year>2011</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1872-7727 (Electronic)&#xD;0720-048X (Linking)</isbn><accession-num>19713064</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/19713064</url></related-urls></urls><electronic-resource-num>10.1016/j.ejrad.2009.07.025</electronic-resource-num></record></Cite></EndNote>67 Semi-quantitative analysis of contrast-enhanced studies is based on the calculation of signal-time curves, signal-to-noise ratios, and contrast-to-noise ratios with region-of-interest analysis of lung tissue signal. Absolute quantification remains difficult due to the non-linear relationship of contrast material concentration and T1-shortening effects; hence the injected amount of contrast material has to be chosen carefully. ADDIN EN.CITE ,  Because perfusion MRI relies on contrast material that is approved for clinical use and standard MRI scanner hardware, it is one of the most straightforward and robust functional pulmonary MRI approaches. HYPERLINK \l "_ENREF_47" \o "Biederer, 2012 #4547"  ADDIN EN.CITE <EndNote><Cite><Author>Biederer</Author><Year>2012</Year><RecNum>4547</RecNum><DisplayText><style face="superscript">47</style></DisplayText><record><rec-number>4547</rec-number><foreign-keys><key app="EN" db-id="zvx0p0vtmtxre0esfsrxfevg0rafdvdtz90s">4547</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Biederer, J.</author><author>Beer, M.</author><author>Hirsch, W.</author><author>Wild, J.</author><author>Fabel, M.</author><author>Puderbach, M.</author><author>Van Beek, E. J.</author></authors></contributors><auth-address>University Hospital Schleswig-Holstein, Campus Kiel, Department of Diagnostic Radiology, Arnold-Heller-Strasse 3, Haus 23, 24105, Kiel, Germany, juergen.biederer@rad.uni-kiel.de.</auth-address><titles><title>MRI of the lung (2/3). Why ... when ... how?</title><secondary-title>Insights Imaging</secondary-title></titles><periodical><full-title>Insights Imaging</full-title><abbr-1>Insights into imaging</abbr-1></periodical><pages>355-71</pages><volume>3</volume><number>4</number><dates><year>2012</year><pub-dates><date>Aug</date></pub-dates></dates><isbn>1869-4101 (Electronic)&#xD;1869-4101 (Linking)</isbn><accession-num>22695944</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22695944</url></related-urls></urls><custom2>3481084</custom2><electronic-resource-num>10.1007/s13244-011-0146-8</electronic-resource-num></record></Cite></EndNote>47  A nearly finalized multi-centre trial of 600 COPD patients that evaluates first pass perfusion MRI and CT will certainly provide insights into the clinical value and feasibility of first pass perfusion MRI. ADDIN EN.CITE ,
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Multinuclear MRI with Inhaled Gas-Contrast 
MRI with inhaled hyperpolarized 3He or 129Xe gas provides another way of obtaining pulmonary structural and functional measurements.72  Parenchyma microstructural information can be obtained using a variety of diffusion-weighted MR pulse sequences.  During inspiration breath-hold, the gas diffuses within the lung micro-structure and the “apparent” diffusion coefficient (ADC) is derived such that it reflects the level of restriction of the gas to diffusion.  Studies have shown that 3He and 129Xe diffusion-weighted measurements are significantly correlated with histology in ex-vivo lungs. ADDIN EN.CITE ,  In addition to lung microstructural information, ventilation images that show the regional distribution of inhaled gas may be acquired.  Static ventilation images have been quantified in a number of ways, including ventilation defect counting or scoring, ADDIN EN.CITE , as well as more automated measurements using manual segmentation, ADDIN EN.CITE 75 thresholding77 or more complex algorithms. ADDIN EN.CITE 78-80  Finally, unlike hyperpolarized 3He gas, hyperpolarized 129Xe gas is soluble in blood and tissues making it possible to measure regional perfusion ADDIN EN.CITE 81 and alveolar transport kinetics. ADDIN EN.CITE 82  While there is still limited clinical experience using this approach in COPD patients, measurements have been shown to be strongly associated with the diffusing capacity of the lung for carbon monoxide (DLCO) in patients with idiopathic pulmonary fibrosis, ADDIN EN.CITE 83 and therefore there is strong potential to phenotype COPD patients using hyperpolarized 129Xe MRI. 
3He and 129Xe static ventilation images and diffusion-weighted images are shown in Figure 2 for a single healthy volunteer and three COPD patients in whom 3He and 129Xe ventilation defects are readily visualized.  The 3He and 129Xe ADC maps are also brighter reflecting larger ADC numbers for the COPD subjects indicative of airspace enlargement and/or emphysematous tissue destruction.  
Other approaches, such as MRI with inhaled fluorinated gases have also been investigated in patients with COPD.  Although 19F MRI has reduced image quality in comparison to hyperpolarized noble gas MRI, 19F MRI has the advantage that it does not require specialized and expensive polarization equipment, and therefore has potential for more widespread use.  19F MRI is still very early in development and although quantitative measurements have yet to be developed, 19F MRI  images show more heterogeneous signal intensity with observable ventilation defects in COPD compared to healthy volunteers.84

Optical Coherence Tomography Imaging Measurements of COPD
Optical coherence tomography (OCT) is most commonly used for coronary artery and retinal imaging.  Recently, investigators have begun to explore the use of OCT for airway diseases because of the very high resolution (approximately 15μm axial resolution) images that may be acquired.  OCT imaging can be performed during bronchoscopic procedures and are limited only by the diameter of airway that can be accessed using the OCT probe.  Typical OCT probes are 1.5mm in diameter, and therefore the small airways that are the site of airflow limitation in COPD ADDIN EN.CITE 85 can be evaluated.  Figure 3 shows OCT images obtained in a proximal airway (approximately 3mm in diameter) and a peripheral airway along the same airway path with the same diameter as the 1.5mm diameter OCT probe for four ex-smokers with and without airflow limitation.  In comparison to the ex-smokers without COPD, who have notably thickened airway walls, the ex-smokers with COPD have larger alveoli and greater destruction of the airway wall.
While OCT airway imaging has been used more extensively to evaluate cancer, ADDIN EN.CITE ,  in COPD patients airway wall OCT measurements are highly reproducible88 and are significantly associated with pulmonary function measurements and CT airway wall measurements. ADDIN EN.CITE 28  Although measuring treatment changes have not yet been demonstrated in COPD patients, OCT has been shown to identify changes in the airway wall following bronchial thermoplasty in asthma. ADDIN EN.CITE 89  It is also possible to obtain information related to the elastic properties of the airway using OCT by measuring the airway diameter at various airway pressures and deriving airway compliance measurements. ADDIN EN.CITE 90  

Pulmonary Imaging to improve COPD patient MANAGEMENT
How is Imaging Currently Used in COPD Patient Management? 
In current clinical practice, imaging is not routinely acquired for COPD patients.  Moreover, chest imaging was not included in recommendations for COPD patient management from the Canadian Thoracic Society ADDIN EN.CITE 91 or in European reports, ADDIN EN.CITE 92 and imaging was only noted as valuable in excluding alternative diagnoses and establishing the presence of comorbidities in the GOLD Executive Summary. ADDIN EN.CITE 1  In fact, one of the only instances where CT has been mentioned as useful in COPD management decisions was for lung volume reduction therapies. ADDIN EN.CITE 93  The National Emphysema Treatment Trial (NETT)8 demonstrated that patients with severe COPD with a predominance of CT emphysema in the upper lobes and reduced exercise capacity may experience improved outcomes and survival following lung volume reduction surgery compared to standard medical therapy.  Thoracic imaging is also used in COPD patient management when planning endobronchial valve placement.  Significant improvements in pulmonary function have been shown in COPD patients with heterogeneous emphysema and intact interlobar fissures. ADDIN EN.CITE , HYPERLINK \l "_ENREF_72" \o "Vestbo, 2011 #1689" 
Potential Role of Quantitative Imaging?
The quantitative imaging field is rapidly developing, and in concert with emerging imaging informatics tools, large quantities of imaging information can be mined to determine image features that predict outcomes following interventions.  For example, the NETT study demonstrated that the regional distribution of emphysema is a clinically important feature to help select patients who better respond to lung volume reduction surgery,8 however there have been numerous others, particularly from the large, multicentre cohort studies, including COPDGene,95  ECLIPSE ADDIN EN.CITE 96 and SPIROMICS.97  For instance, the presence of CT emphysema predicts lung function decline; ADDIN EN.CITE 94 CT emphysema extent predicts response to certain COPD treatments; ADDIN EN.CITE 98 CT emphysema extent and airway dimension measurements predict mortality; ADDIN EN.CITE 99 CT emphysema extent and airway dimension measurements, ADDIN EN.CITE 100 as well as MRI ventilation defect measurements, ADDIN EN.CITE 101 may predict COPD exacerbations that require hospitalizations.  Other quantitative imaging measurements, namely pulmonary artery enlargement (PA:A ratio measured on CT >1) were also shown to be associated with severe exacerbations of COPD. ADDIN EN.CITE 102  Importantly, the genetic determinants of these quantitative imaging phenotypes are also being investigated, ADDIN EN.CITE , and large multi-centre cohort studies incorporating multi-modality imaging, such as the German ASCONET study, will certainly help provide more insight into the clinical value and feasibility of thoracic imaging in COPD patients. ADDIN EN.CITE 70  
More research is required to investigate whether quantitative imaging may help identify phenotypes that will enable effective COPD management to improve outcomes. Furthermore, linking information from multiple scales, from disease endotype to imaging phenotype, may improve how COPD patients are managed at all levels from drug discovery, such that there are more treatment options for patients with COPD, to real-time incorporation of quantitative imaging into patient management decisions.

CONCLUSIONS
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